Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients

Nutrients

Volumn 8, Issue 11, 2016, Pages

  Zheng, Jing Quan ^a,b   Hou, Yi Chou ^c   Zheng, Cai Mei ^a,b,d   Lu, Chien Lin ^b   Liu, Wen Chih ^b,c   Wu, Chia Chao ^e   Huang, Ming Te ^a   Lin, Yuh Feng ^a,b,d   Lu, Kuo Cheng ^b,c,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cholecalciferol; Human cathelicidin (hCAP 18); Maintenance hemodialysis (HD); Paricalcitol; Secondary hyperparathyroidism (SHPT); Study

Indexed keywords

CALCIFEDIOL; CATHELICIDIN; COLECALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; ERGOCALCIFEROL; VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION; BLOOD; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; COMPLICATION; DRUG INTERACTION; HYPERPARATHYROIDISM, SECONDARY; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIMICROBIAL CATIONIC PEPTIDES; CALCIFEDIOL; CHOLECALCIFEROL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PLACEBOS; RENAL DIALYSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 84995530884     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8110708     Document Type: Article

References (48)

1. Lomashvili, K.A.; Wang, X.; O’Neill, W.C. Role of local versus systemic vitamin D receptors in vascular calcification. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 146–151. [CrossRef]
2. Briese, S.; Wiesner, S.; Will, J.C.; Lembcke, A.; Opgen-Rhein, B.; Nissel, R.; Wernecke, K.D.; Andreae, J.; Haffner, D.; Querfeld, U. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol. Dial. Transplant. 2006, 21, 1906–1914. [CrossRef]
3. Gomez-Alonso, C.; Naves-Diaz, M.L.; Fernandez-Martin, J.L.; Diaz-Lopez, J.B.; Fernandez-Coto, M.T.; Cannata-Andia, J.B. Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxyvitamin D cut-off levels. Kidney Int. 2003, 63, S44–S48. [CrossRef]
4. Harkness, L.; Cromer, B. Low levels of 25-hydroxy vitamin D are associated with elevated parathyroid hormone in healthy adolescent females. Osteoporos. Int. 2005, 16, 109–113. [CrossRef]
5. Hollis, B.W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J. Nutr. 2005, 135, 317–322.
6. Vieth, R.; Ladak, Y.; Walfish, P.G. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J. Clin. Endocrinol. Metab. 2003, 88, 185–191. [CrossRef]
7. Ooms, M.E.; Lips, P.; Roos, J.C.; van der Vijgh, W.J.; Popp-Snijders, C.; Bezemer, P.D.; Bouter, L.M. Vitamin D status and sex hormone binding globulin: Determinants of bone turnover and bone mineral density in elderly women. J. Bone Miner. Res. 1995, 10, 1177–1184. [CrossRef]
8. Dusso, A.; Brown, A.; Slatopolsky, E. Extrarenal production of calcitriol. Semin. Nephrol. 1994, 14, 144–155.
9. Zehnder, D.; Bland, R.; Williams, M.C.; McNinch, R.W.; Howie, A.J.; Stewart, P.M.; Hewison, M. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001, 86, 888–894.
10. Wolf, M.; Shah, A.; Gutierrez, O.; Ankers, E.; Monroy, M.; Tamez, H.; Steele, D.; Chang, Y.; Camargo, C.A., Jr.; Tonelli, M.; et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007, 72, 1004–1013. [CrossRef]
11. Levin, A.; Bakris, G.L.; Molitch, M.; Smulders, M.; Tian, J.; Williams, L.A.; Andress, D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007, 71, 31–38. [CrossRef]
12. Ishimura, E.; Nishizawa, Y.; Inaba, M.; Matsumoto, N.; Emoto, M.; Kawagishi, T.; Shoji, S.; Okuno, S.; Kim, M.; Miki, T.; et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999, 55, 1019–1027. [CrossRef]
13. Drechsler, C.; Verduijn, M.; Pilz, S.; Dekker, F.W.; Krediet, R.T.; Ritz, E.; Wanner, C.; Boeschoten, E.W.; Brandenburg, V.; Group, N.S. Vitamin D status and clinical outcomes in incident dialysis patients: Results from the necosad study. Nephrol. Dial. Transplant. 2011, 26, 1024–1032. [CrossRef]
14. Segersten, U.; Correa, P.; Hewison, M.; Hellman, P.; Dralle, H.; Carling, T.; Akerstrom, G.; Westin, G. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab. 2002, 87, 2967–2972.
15. Correa, P.; Segersten, U.; Hellman, P.; Akerstrom, G.; Westin, G. Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors—New prospects for treatment of hyperparathyroidism with vitamin D. J. Clin. Endocrinol. Metab. 2002, 87, 5826–5829. [CrossRef]
16. Ritter, C.S.; Armbrecht, H.J.; Slatopolsky, E.; Brown, A.J. 25-hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006, 70, 654–659. [CrossRef]
17. Rojas-Rivera, J.; De La Piedra, C.; Ramos, A.; Ortiz, A.; Egido, J. The expanding spectrum of biological actions of vitamin D. Nephrol. Dial. Transplant. 2010, 25, 2850–2865. [CrossRef]
18. Kalantar-Zadeh, K.; Kovesdy, C.P. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 1529–1539. [CrossRef]
19. Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S.; et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173, 2909–2912. [CrossRef]
20. Yim, S.; Dhawan, P.; Ragunath, C.; Christakos, S.; Diamond, G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J. Cyst. Fibros. 2007, 6, 403–410. [CrossRef]
21. Hewison, M. Vitamin D and immune function: Autocrine, paracrine or endocrine? Scand. J. Clin. Lab. Investig. 2012, 72 (Suppl S243), 92–102.
22. Yuk, J.M.; Shin, D.M.; Lee, H.M.; Yang, C.S.; Jin, H.S.; Kim, K.K.; Lee, Z.W.; Lee, S.H.; Kim, J.M.; Jo, E.K. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009, 6, 231–243. [CrossRef]
23. Smolders, J.; Thewissen, M.; Peelen, E.; Menheere, P.; Tervaert, J.W.; Damoiseaux, J.; Hupperts, R. Vitamin D status is positively correlated with regulatory t cell function in patients with multiple sclerosis. PLoS ONE 2009, 4, e6635. [CrossRef]
24. Gombart, A.F.; Bhan, I.; Borregaard, N.; Tamez, H.; Camargo, C.A., Jr.; Koeffler, H.P.; Thadhani, R. Low plasma level of cathelicidin antimicrobial peptide (HCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin. Infect. Dis. 2009, 48, 418–424. [CrossRef]
25. Faul, F.; Erdfelder, E.; Lang, A.G.; Buchner, A. Gpower 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39, 175–191. [CrossRef]
26. Ding, C.; Gao, D.; Wilding, J.; Trayhurn, P.; Bing, C. Vitamin D signalling in adipose tissue. Br. J. Nutr. 2012, 108, 1915–1923. [CrossRef]
27. Bell, N.H.; Shaw, S.; Turner, R.T. Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man. J. Clin. Investig. 1984, 74, 1540–1544. [CrossRef]
28. Pike, J.W.; Meyer, M.B. Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyvitamin D(3) action. Arch. Biochem. Biophys. 2012, 523, 2–8. [CrossRef]
29. Echida, Y.; Mochizuki, T.; Uchida, K.; Tsuchiya, K.; Nitta, K. Risk factors for vitamin D deficiency in patients with chronic kidney disease. Intern. Med. 2012, 51, 845–850. [CrossRef]
30. Metzger, M.; Houillier, P.; Gauci, C.; Haymann, J.P.; Flamant, M.; Thervet, E.; Boffa, J.J.; Vrtovsnik, F.; Froissart, M.; Stengel, B.; et al. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: Quest for a threshold. J. Clin. Endocrinol. Metab. 2013, 98, 2922–2928. [CrossRef]
31. Fournier, A.; Harbouche, L.; Mansour, J.; Shahapuni, I. Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset end stage renal disease. Nephrol. Dial. Transplant. 2007, 22, 956–957. [CrossRef]
32. Liu, W.C.; Wu, C.C.; Hung, Y.M.; Liao, M.T.; Shyu, J.F.; Lin, Y.F.; Lu, K.C.; Yeh, K.C. Pleiotropic effects of vitamin D in chronic kidney disease. Clin. Chim. Acta 2016, 453, 1–12. [CrossRef]
33. Armas, L.A.; Andukuri, R.; Barger-Lux, J.; Heaney, R.P.; Lund, R. 25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin. J. Am. Soc. Nephrol. 2012, 7, 1428–1434. [CrossRef]
34. Bansal, B.; Bansal, S.B.; Mithal, A.; Kher, V.; Marwaha, R.; Singh, P.; Irfan, N. A randomized controlled trial of cholecalciferol supplementation in patients on maintenance hemodialysis. Indian J. Endocrinol. Metab. 2014, 18, 655–661.
35. Delanaye, P.; Weekers, L.; Warling, X.; Moonen, M.; Smelten, N.; Medart, L.; Krzesinski, J.M.; Cavalier, E. Cholecalciferol in haemodialysis patients: A randomized, double-blind, proof-of-concept and safety study. Nephrol. Dial. Transplant. 2013, 28, 1779–1786. [CrossRef]
36. Dusilova-Sulkova, S.; Safranek, R.; Vavrova, J.; Horacek, J.; Pavlikova, L.; Palicka, V. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. Int. Urol. Nephrol. 2015, 47, 169–176. [CrossRef]
37. Dogan, E.; Erkoc, R.; Sayarlioglu, H.; Soyoral, Y.; Dulger, H. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren. Fail. 2008, 30, 407–410. [CrossRef]
38. Bhan, I.; Dobens, D.; Tamez, H.; Deferio, J.J.; Li, Y.C.; Warren, H.S.; Ankers, E.; Wenger, J.; Tucker, J.K.; Trottier, C.; et al. Nutritional vitamin D supplementation in dialysis: A randomized trial. Clin. J. Am. Soc. Nephrol. 2015, 10, 611–619. [CrossRef]
39. Liu, W.C.; Zheng, C.M.; Lu, C.L.; Lin, Y.F.; Shyu, J.F.; Wu, C.C.; Lu, K.C. Vitamin D and immune function in chronic kidney disease. Clin. Chim. Acta 2015, 450, 135–144. [CrossRef]
40. DiNubile, M.J. Understanding the high infectious disease mortality among patients receiving hemodialysis: Potential risk of concurrently low cathelicidin and gelsolin levels. Clin. Infect. Dis. 2009, 49, 163–164.
41. Leaf, D.E.; Croy, H.E.; Abrahams, S.J.; Raed, A.; Waikar, S.S. Cathelicidin antimicrobialprotein, vitamin D, and risk of death in critically ill patients. Crit. Care 2015, 19, 80. [CrossRef]
42. McMahon, L.; Schwartz, K.; Yilmaz, O.; Brown, E.; Ryan, L.K.; Diamond, G. Vitamin D-mediated induction of innate immunity in gingival epithelial cells. Infect. Immun. 2011, 79, 2250–2256. [CrossRef]
43. Liu, P.T.; Stenger, S.; Tang, D.H.; Modlin, R.L. Cutting edge: Vitamin D-mediated human antimicrobial activity against mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 2007, 179, 2060–2063. [CrossRef]
44. Gombart, A.F.; Saito, T.; Koeffler, H.P. Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genom. 2009, 10, 321. [CrossRef]
45. Larcombe, L.; Mookherjee, N.; Slater, J.; Slivinski, C.; Dantouze, J.; Singer, M.; Whaley, C.; Denechezhe, L.; Matyas, S.; Decter, K.; et al. Vitamin D, serum 25(OH)D, LL-37 and polymorphisms in a Canadian first nation population with endemic tuberculosis. Int. J. Circumpolar Health 2015, 74, 28952. [CrossRef]
46. Bacchetta, J.; Chun, R.F.; Gales, B.; Zaritsky, J.J.; Leroy, S.; Wesseling-Perry, K.; Boregaard, N.; Rastogi, A.; Salusky, I.B.; Hewison, M. Antibacterial responses byperitoneal macrophages are enhanced following vitamin D supplementation. PLoS ONE 2014, 30, e116530.
47. Lachmann, R.; Bevan, M.A.; Kim, S.; Patel, N.; Hawrylowicz, C.; Vyakarnam, A.; Peters, B.S. A comparative phase 1 clinical trial to identify anti-infective mechanisms of vitamin D in people with HIV infection. AIDS 2015, 19, 1127–1135. [CrossRef]
48. Quraishi, S.A.; De Pascale, G.; Needleman, J.S.; Nakazawa, H.; Kaneki, M.; Bajwa, E.K.; Camargo, C.A., Jr.; Bhan, I. Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in sepsis: A randomized, placebo-controlled trial. Crit. Care Med. 2015, 43, 1928–1937. [CrossRef]